University of East Anglia, Norwich, UK.
BMC Pulm Med. 2012 Jul 2;12:33. doi: 10.1186/1471-2466-12-33.
Manual chest physiotherapy (MCP) techniques involving chest percussion, vibration, and shaking have long been used in the treatment of respiratory conditions. However, methodological limitations in existing research have led to a state of clinical equipoise with respect to this treatment. Thus, for patients hospitalised with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), clinical preference tends to dictate whether MCP is given to assist with sputum clearance. We standardised the delivery of MCP and assessed its effectiveness on disease-specific quality of life.
In this randomised, controlled trial powered for equivalence, 526 patients hospitalised with acute COPD exacerbation were enrolled from four centres in the UK. Patients were allocated to receive MCP plus advice on airway clearance or advice on chest clearance alone. The primary outcome was a COPD specific quality of life measure, the Saint Georges Respiratory Questionnaire (SGRQ) at six months post randomisation. Analyses were by intention to treat (ITT). This study was registered, ISRCTN13825248.
All patients were included in the analyses, of which 372 (71%) provided evaluable data for the primary outcome. An effect size of 0·3 standard deviations in SGRQ score was specified as the threshold for superiority. The ITT analyses showed no significant difference in SGRQ for patients who did, or did not receive MCP (95% CI -0·14 to 0·19).
These data do not lend support to the routine use of MCP in the management of acute exacerbation of COPD. However, this does not mean that MCP is of no therapeutic value to COPD patients in specific circumstances.
手动胸部物理疗法(MCP)技术包括胸部叩击、振动和抖动,长期以来一直用于治疗呼吸系统疾病。然而,现有研究中的方法学限制导致了这种治疗方法的临床平衡状态。因此,对于因慢性阻塞性肺疾病(COPD)加重而住院的患者,临床偏好往往决定是否给予 MCP 以帮助清除痰液。我们对 MCP 的实施进行了标准化,并评估了其对特定于疾病的生活质量的影响。
在这项针对等效性的随机对照试验中,从英国的四个中心招募了 526 名因急性 COPD 加重而住院的患者。患者被分配接受 MCP 加气道清除建议或仅接受胸部清除建议。主要结局是 COPD 特定生活质量测量,即圣乔治呼吸问卷(SGRQ)在随机分组后六个月。分析采用意向治疗(ITT)。这项研究已注册,ISRCTN13825248。
所有患者均纳入分析,其中 372 名(71%)提供了主要结局的可评估数据。SGRQ 评分 0.3 标准差的效应大小被指定为优势的阈值。ITT 分析显示,接受或不接受 MCP 的患者在 SGRQ 方面没有显著差异(95%CI-0.14 至 0.19)。
这些数据不支持在 COPD 急性加重的管理中常规使用 MCP。然而,这并不意味着 MCP 在特定情况下对 COPD 患者没有治疗价值。